Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Lancet Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S1474-4422(08)70261-8PMID 19042161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Analyses of mortality risk in patients with dementia treated with galantamine

  2009cited by this paper
• Safety and efficacy of galantamine in subjects with mild cognitive impairment

  2008cited by this paper
• Donepezil preserves cognition and global function in patients with severe Alzheimer disease

  2007cited by this paper
• Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment

  2007cited by this paper
• Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

  2006cited by this paper
• Galantamine for Alzheimer's disease and mild cognitive impairment.

  2006cited by this paper
• Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment

  2006cited by this paper
• Determinants of costs of care for patients with Alzheimer's disease

  2006cited by this paper
• The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

  2006cited by this paper
• Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial

  2005cited by this paper
• Activities of Daily Living in Patients with Dementia

  2004cited by this paper
• Community-acquired pneumonia in the elderly.

  2003cited by this paper
• Number of dementia sufferers in Europe between the years 2000 and 2050

  2003cited by this paper
• Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• GALANTAMINE PROVIDES BROAD BENEFITS IN PATIENTS WITH ‘ADVANCED MODERATE’ ALZHEIMER'S DISEASE (MMSE ≤12) FOR UP TO SIX MONTHS

  2002cited by this paper
• Patient and caregiver characteristics and nursing home placement in patients with dementia.

  2002cited by this paper
• A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease

  2001cited by this paper
• Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

  2000cited by this paper
• Community-acquired pneumonia in the elderly.

  2000cited by this paper
• A 5-month, randomized, placebo-controlled trial of galantamine in AD

  2000cited by this paper
• Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension

  2000cited by this paper
• Galantamine in AD

  2000cited by this paper
• Scaling ADLs within the MDS.

  1999cited by this paper
• Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project

  1998cited by this paper
• Development of the nursing home Resident Assessment Instrument in the USA.

  1997cited by this paper
• Bone density measurement : a systematic review : a report from SBU, the Swedish Council on Technology Assessment in Health Care

  1997cited by this paper
• Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors.

  1996cited by this paper
• Severe impairment battery. A neuropsychological test for severely demented patients.

  1994cited by this paper
• Vascular dementia

  1993cited by this paper
• The Test for Severe Impairment: An Instrument for the Assessment of Patients with Severe Cognitive Dysfunction

  1992cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine

  2025cites this paper
• Identification and experimental validation of Alzheimer's disease hub genes via bioinformatics and machine learning

  2025cites this paper
• Exploring the Efficacy and Target Genes of Atractylodes Macrocephala Koidz Against Alzheimer’s Disease Based on Multi-Omics, Computational Chemistry, and Experimental Verification

  2025cites this paper
• Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease

  2025cites this paper
• A Scoping Review of Interventions Using an interRAI Information System to Guide Care Management and Assess Intervention Efficacy in Older Adults

  2025cites this paper
• Self-assembled DNA micelle-GNP for simultaneous detecting miRNAs of Alzheimer's disease via lateral flow assays.

  2025cites this paper
• Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia.

  2025cites this paper
• Alkaloid’s undiscovered neuroprotective potential: a multi-target strategy to fight against neurodegenerative illnesses

  2025cites this paper
• Targeting glial dysfunction in Alzheimer’s disease: insights into pathogenesis and emerging therapeutics

  2025cites this paper
• Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.

  2024cites this paper
• Anti-dementia drugs: what is the evidence in advanced stages?

  2024cites this paper
• Exploring the Impact of Vitamin B12 Deficiency on Central Nervous System and Cardiovascular Health: A Comprehensive Overview

  2024cites this paper
• Efficacy of exercise rehabilitation for managing patients with Alzheimer’s disease

  2023cites this paper
• Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer’s Disease Clinical Trials

  2023cites this paper
• Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales

  2023cites this paper
• Analysis on the thermal decomposition kinetics and storage period of biomass-based lycorine galanthamine

  2023cites this paper
• The influence of heat stress on the antioxidant protection glutathione link and the content of lipid peroxidation products in chicken liver

  2023cites this paper
• Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis.

  2023cites this paper
• Effectiveness of treatments for people living with severe dementia: A systematic review and meta-analysis of randomised controlled clinical trials

  2022cites this paper
• An Efficient Matrix Solid-Phase Dispersion Extraction Combined with Online Preconcentration by Electrokinetic Supercharging in Capillary Electrophoresis for the Sensitive Determination of Two Alkaloids in Complicated Samples Matrix

  2022cites this paper
• Association Between Cholinesterase Inhibitors and New-Onset Heart Failure in Patients With Alzheimer's Disease: A Nationwide Propensity Score Matching Study

  2022cites this paper
• Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis

  2022influential citation
• Unravelling Binding of Human Serum Albumin with Galantamine: Spectroscopic, Calorimetric, and Computational Approaches

  2022cites this paper
• Anti-dementia Medication

  2021cites this paper
• Role of Vitamins in Neurodegenerative Diseases: A Review.

  2021cites this paper
• Palliative care interventions in advanced dementia.

  2021cites this paper
• Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease

  2021cites this paper
• Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis

  2021cites this paper
• Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials

  2021cites this paper
• Alzheimer's Disease Pharmacology

  2021cites this paper
• Pharmacological exploration of traditional plants for the treatment of neurodegenerative disorders

  2020cites this paper
• Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.

  2020cites this paper
• Genistein and Galantamine Combinations Decrease β-Amyloid Peptide (1–42)–Induced Genotoxicity and Cell Death in SH-SY5Y Cell Line: an In Vitro and In Silico Approach for Mimic of Alzheimer’s Disease

  2020cites this paper
• The Effects of Lower BP Goals on Cognitive Function in the Elderly

  2020cites this paper
• Deficiency of vitamin B12 and its relation with neurological disorders: a critical review

  2020cites this paper
• Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia

  2020cites this paper
• Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy

  2020cites this paper
• Evaluation of the Therapeutic Effect of Lycoramine on Alzheimer's Disease in Mouse Model.

  2020cites this paper
• Current clinical approaches in neurodegenerative diseases

  2020cites this paper
• Acetylcholinesterase inhibitory agents in plants and their application to dementia

  2020cites this paper
• Factors Associated With Deprescribing Acetylcholinesterase Inhibitors in Older Nursing Home Residents With Severe Dementia

  2019cites this paper
• Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)

  2019cites this paper
• Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease

  2019cites this paper
• Reducing inappropriate prescribing for older adults with advanced frailty: A review based on a survey of practice in four countries.

  2019cites this paper
• Risk for Health Events After Deprescribing Acetylcholinesterase Inhibitors in Nursing Home Residents With Severe Dementia

  2019cites this paper
• Pharmacological Interventions in Older Adults

  2019cites this paper
• Neurocognitive Disorders in Old Age: Alzheimer’s Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases

  2019cites this paper
• Primary Care Mental Health in Older People: A Global Perspective

  2019cites this paper
• Dementíé?

  2019cites this paper
• Therapeutic Class Overview Alzheimer ’ s Disease Agents

  2018cites this paper
• The Severe Impairment Battery

  2018cites this paper
• Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice

  2018cites this paper
• Schisandrin ameliorates cognitive impairment and attenuates Aβ deposition in APP/PS1 transgenic mice: involvement of adjusting neurotransmitters and their metabolite changes in the brain

  2018cites this paper
• A Computer-Assisted Systematic Search for Melatonin Derivatives with High Potential as Antioxidants

  2018cites this paper
• Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists

  2018cites this paper
• Galantamine inhibits β‐amyloid‐induced cytostatic autophagy in PC12 cells through decreasing ROS production

  2018cites this paper
• UPLC-MS/MS method for determination of schisandrin in rat plasma and brain microdialysates: application to a comparative pharmacokinetic and brain distribution study in normal and Alzheimer’s disease rats

  2017cites this paper
• Simultaneous electrochemiluminescence determination of galanthamine, homolycorine, lycorenine, and tazettine in Lycoris radiata by capillary electrophoresis with ultrasonic-assisted extraction.

  2017cites this paper
• Geriatric Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Depression, Dementia, and Dementia-Related Disorders in the Elderly

  2017cites this paper
• Focused ultrasound as a novel strategy for Alzheimer disease therapeutics

  2017cites this paper
• Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias.

  2017cites this paper
• Amary llidaceae Perspectives In Alzheimer´S Disease

  2016cites this paper
• Galanthamine decreases genotoxicity and cell death induced by β-amyloid peptide in SH-SY5Y cell line.

  2016cites this paper
• Vertically encoded tetragonal hydrogel microparticles for multiplexed detection of miRNAs associated with Alzheimer's disease.

  2016cites this paper
• Galantamine for Alzheimer’s Disease and Alzheimer’s Disease with Cerebrovascular Disease

  2016cites this paper
• Treatment of Alzheimer's Disease: Classical Therapeutic Approach

  2016cites this paper
• Palliative care interventions in advanced dementia.

  2016cites this paper
• Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease

  2016cites this paper
• Revista Española de Geriatría y Gerontología

  2016cites this paper
• Alzheimer’s disease and language impairments: social intervention and medical treatment

  2015cites this paper
• Medications used in dementia: a review of evidence

  2015cites this paper
• Efficacy and safety of galantamine treatment for patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials

  2015influential citation
• Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer’s Disease Mice

  2015cites this paper
• Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials.

  2015cites this paper
• Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?

  2015cites this paper
• A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence

  2015cites this paper
• Curcumin and Neurological/Brain Disorders

  2015cites this paper
• Therapeutic Class Overview Alzheimer's Agents

  2014cites this paper
• Investigação de associação entre a Butirilcolinesterase e a doença de Alzheimer

  2014cites this paper
• Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis

  2014cites this paper
• Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting

  2014cites this paper
• A Meta-Analysis of the Efficacy of Donepezil, Rivastigmine, Galantamine, and Memantine in Relation to Severity of Alzheimer's Disease

  2013influential citation
• S3-Leitlinien Demenzen

  2013cites this paper
• A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia

  2013cites this paper
• Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology

  2013cites this paper
• Somatic comorbidities and Alzheimer’s disease treatment

  2013cites this paper
• Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors

  2013cites this paper
• Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

  2013cites this paper
• [Report: an analysis of publications by members of the Spanish Geriatrics and Gerontology Society from 2006 to 2011].

  2013cites this paper
• Cholinesterasehemmer zur Therapie der Alzheimerschen Krankheit: Gibt es klinisch relvante Unterschiede?

  2013cites this paper
• Effect of galantamine on platelet functions in healthy elderly people

  2013cites this paper
• Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

  2013cites this paper
• Is Drug Treatment for Dementia Followed Up in Primary Care? A Swedish Study of Dementia Clinics and Referring Primary Care Centres

  2013cites this paper
• Cholinesterase inhibitors and memantine for symptomatic treatment of dementia

  2012cites this paper
• Pharmacological treatment of dementia

  2012cites this paper
• Essential Evidence-Based Psychopharmacology: Evidence-based pharmacotherapy of Alzheimer's disease

  2012cites this paper
• Promising Therapeutics with Natural Bioactive Compounds for Improving Learning and Memory — A Review of Randomized Trials

  2012influential citation
• Consensus 2012 sur le diagnostic et le traitement des patients atteints de démence en Suisse

  2012cites this paper
• Drug Therapy Optimization at the End of Life

  2012cites this paper
• Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.

  2012cites this paper